AgingNCT06956131
Metabolite Changes Following Consumption Of Different Protein Drinks In Singapore Older Adults
A study testing Casein Protein Isolate Drink, Whey Protein Isolate Drink and Soy Protein Isolate Drink in people with Aging and Protein Metabolism, run by National University of Singapore at 1 site in Singapore.
Trial summary
The study aims to investigate the acute effects of different protein sources (i.e., casein, whey, soy) on metabolomic profiles (e.g., amino acids in the blood), along with other outcomes such as cognitive function, mood, and appetite. Read more about this study
- Who is it for?
- Ages 60 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Aging, Protein Metabolism
- What is being tested?
- Casein Protein Isolate Drink, Whey Protein Isolate Drink and Soy Protein Isolate Drink
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 32 participants
- Where
- 1 siteSingapore
- Study dates
- 20 May 2025to Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- English-literate and able to give informed consent
- Adults 60 to 80 years old (inclusive)
- (If applicable) Postmenopausal
- BMI of 18·5 to 30 kg/m2 (inclusive)
Who cannot join
- Currently participating in another clinical study that involves altering the regular diet and/or involves consuming a dietary supplement or investigated food product as an intervention
- Weight change >3 kg in the past 3 months
- Exercising vigorously over the past 3 months (i.e., engaging in high-intensity exercises for more than 3 hours a week, where high-intensity exercises leave one out of breath and unable to talk or sing during the workout)
- Current smokers or have quit smoking for less than 5 years
- Drinking >2 alcoholic drinks per day (i.e., one drink is defined as either 150 ml of wine, 340 ml of beer/cider or 45 ml of distilled spirit)
- If drinking ≤2 alcoholic drinks per day, not willing to stop consumption of alcoholic beverages two days before and on the day of the test visits (total 12 days)
Show all 17Show fewer
- Not willing to stop consumption of caffeinated beverages 10 to 12 hours before and on the day of the test visits (total 4 days)
- Taking supplements containing omega-3, magnesium, gamma-aminobutyric acid (GABA), L-theanine, melatonin and/or 5-hydroxytryptophan for the past 3 months, and not willing to discontinue usage 3 months before and during the study duration
- Currently on a specialised diet (e.g., vegetarian, vegan, weight loss diet)
- Had serious food allergies in the past, or having intolerance, sensitivities or allergies to any of the following: milk/dairy products (e.g., casein, whey), starch/starch-derived products (e.g., rice, corn, wheat, potato), soy/soy-derived products, gluten, eggs, nuts, peanuts, fish and crustaceans.
- Disease or impairment of the kidney and/or liver
- Currently diagnosed with diabetes, sleep disorders, gastrointestinal issues (e.g., lactose intolerance, irritable bowel syndrome), gout and/or G6PD deficiency
- History of diseases known to affect the central nervous system (e.g., heart disease, stroke, migraine headaches, multiple sclerosis, Parkinson's disease, mental illnesses)
- Taking antibiotics 2 weeks prior to study participation
- Taking medication known to interfere with cognitive function and mental wellbeing (e.g., benzodiazepines, antidepressants, other central nervous agents)
- Taking anti-hypertensive or cholesterol-lowering drugs for less than 3 years unless medically declared by an official doctor to be in stable condition
- Poor peripheral venous access based on past experiences with blood drawing
Trial locations and contacts
1 site in 1 country.
Singapore1 site
NUS, Department of Food Science and Technology, 1 Science Drive 3, Block S13, #03-07
Singapore, 117550
About this study
The study aims to investigate the acute effects of different protein sources (i.e., casein, whey, soy) on metabolomic profiles (e.g., amino acids in the blood), along with other outcomes such as cognitive function, mood, and appetite. While the study does not directly aim to prevent, prognosticate, diagnose, or alleviate any disease, it may provide insights that could inform dietary recommendations and support disease prevention efforts in older adults.
Read the detailed description
This study will be a double-blind, randomised, placebo-controlled trial using a crossover study design. 25 older adults (aged 60 to 80) will be recruited and assigned to consume 4 different test drinks in a random order on 4 different visits. This study aims to investigate whether higher protein consumption of different sources will influence postprandial plasma and urinary metabolomic profiles, cognition, mood and appetite. The study will comprise 1 screening visit and 4 test visits separated separated by a minimum washout period of >7 days
- Conditions
- Aging, Protein Metabolism
- Being tested
- Casein Protein Isolate Drink, Whey Protein Isolate Drink, Soy Protein Isolate Drink, Maltodextrin Drink
- Keywords
- Older adults, Metabolomics, Protein intake, Protein metabolism, Acute, Postprandial, Cognitive function, Mood, Appetite
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Casein Protein Isolate DrinkDietary supplement
30 g protein equivalent of casein protein isolate dissolved in ~250 mL of water
Whey Protein Isolate DrinkDietary supplement
30 g protein equivalent of whey protein isolate dissolved in ~250 mL of water
Soy Protein Isolate DrinkDietary supplement
30 g protein equivalent of soy protein isolate dissolved in ~250 mL of water
Maltodextrin DrinkDietary supplement
30 g carbohydrate equivalent of maltodextrin powder dissolved in ~250 mL of water
| Study group | Role | What they receive |
|---|---|---|
| Casein Protein Drink | Experimental | 30 g protein equivalent of casein protein isolate dissolved in ~250 mL of water Receives: Dietary Supplement: Casein Protein Isolate Drink |
| Whey Protein Drink | Experimental | 30 g protein equivalent of whey protein isolate dissolved in ~250 mL of water Receives: Dietary Supplement: Whey Protein Isolate Drink |
| Soy Protein Drink | Experimental | 30 g protein equivalent of soy protein isolate dissolved in ~250 mL of water Receives: Dietary Supplement: Soy Protein Isolate Drink |
| Maltodextrin Drink | Placebo comparator | 30 g carbohydrate equivalent of maltodextrin powder dissolved in ~250 mL of water Receives: Dietary Supplement: Maltodextrin Drink |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in metabolites found in plasma (plasma metabolomics)
Untargeted metabolomics profiling of plasma will be conducted using ultra performance liquid chromatography-quadrupole time of flight-mass spectrometry (UPLC-QTOF-MS)
Measured: Baseline, 15, 30, 60, 90, 120, 180, 240, 300 minutes
Changes in metabolites found in urine (urinary metabolomics)
Untargeted metabolomics profiling of urine will be conducted using ultra performance liquid chromatography-quadrupole time of flight-mass spectrometry (UPLC-QTOF-MS)
Measured: Baseline, 60, 120, 180, 240, 300 minutes
Secondary outcomes (2)
Cognitive Function
The Computerised Mental Performance Assessment System (COMPASS) will be administered via a laptop. The COMPASS tests consist of 5 consecutive tests, including Digit Vigilance, Stroop, Rapid Visual Information Processing, Computerised Corsi Blocks Lite, Alphabetic Working Memory and Serial Subtraction, where the correctness and reaction time will be recorded. The test is expected to take around 15 minutes.
Measured: Baseline, 15, 60, 120, 180, 240, 300 minutes
Mood
The Profile of Mood States (POMS) questionnaire will be administered, which contains various words that describe feelings. Participants will indicate, for each word, how they currently feel on scale of 0 (Not at all) to 4 (Extremely).
Measured: Baseline, 15, 60, 120, 180, 240, 300 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 May 2025
- Study start20 May 2025
- Primary completion9 Feb 2026
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for AgingStudies of the same condition, open and under way.
- More trials run by National University of SingaporeThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 32 participants (estimated)
Sponsor and investigators
- Lead sponsor
- National University of Singapore
- Sponsor type
- University, hospital or other
- Collaborators
- Bezos Earth Fund
- Responsible party
- Principal investigator, Jung Eun Kim, National University of Singapore
- Investigators
- Jung Eun Kim, Ph.D., R.D., Principal investigator, National University of Singapore, Department of Food Science and Technology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06956131
- Sponsor's protocol ID
- S31
- Other IDs
- NUS-IRB-2025-19
- Status last verified
- Apr 2025
- First submitted
- 15 Apr 2025
- Last updated
- 17 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Electronic copies of the data with identifiable participant information will be kept on NUS OneDrive with access limited only Dr Kim Jung Eun and her research staff. All data will be de-identified prior to statistical analyses.
Publications
Lanng SK, Oxfeldt M, Johansen FT, Risikesan J, Hansen M, Bertram HC. Acute changes in the metabolome following resistance exercise combined with intake of different protein sources (cricket, pea, whey). Metabolomics. 2023 Nov 24;19(12):98. doi: 10.1007/s11306-023-02064-0.
PubMed 37999866
Study at a glance
From the registry record, last updated by the sponsor on 17 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Metabolite Changes Following Consumption Of Different Protein Drinks In Singapore Older Adults
- ClinicalTrials.gov ID
- NCT06956131
- Acronym / sponsor ID
- S31
- Conditions
- Aging, Protein Metabolism
- Keywords
- Older adults, Metabolomics, Protein intake, Protein metabolism, Acute, Postprandial, Cognitive function, Mood
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 32 participants (estimated)
- Lead sponsor
- National University of SingaporeUniversity, hospital or other
- Collaborators
- Bezos Earth Fund
- Study start
- 20 May 2025 (actual)
- Primary completion
- 9 Feb 2026 (actual)
- Study completion
- Dec 2026 (estimated)
- First posted
- 2 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study aims to investigate the acute effects of different protein sources (i.e., casein, whey, soy) on metabolomic profiles (e.g., amino acids in the blood), along with other outcomes such as cognitive function, mood, and appetite. While the study does not directly aim to prevent, prognosticate, diagnose, or alleviate any disease, it may provide insights that could inform dietary recommendations and support disease prevention efforts in older adults.
Detailed description
This study will be a double-blind, randomised, placebo-controlled trial using a crossover study design. 25 older adults (aged 60 to 80) will be recruited and assigned to consume 4 different test drinks in a random order on 4 different visits. This study aims to investigate whether higher protein consumption of different sources will influence postprandial plasma and urinary metabolomic profiles, cognition, mood and appetite. The study will comprise 1 screening visit and 4 test visits separated separated by a minimum washout period of >7 days
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Casein Protein Drink | Experimental | Dietary Supplement: Casein Protein Isolate Drink30 g protein equivalent of casein protein isolate dissolved in ~250 mL of water |
| Whey Protein Drink | Experimental | Dietary Supplement: Whey Protein Isolate Drink30 g protein equivalent of whey protein isolate dissolved in ~250 mL of water |
| Soy Protein Drink | Experimental | Dietary Supplement: Soy Protein Isolate Drink30 g protein equivalent of soy protein isolate dissolved in ~250 mL of water |
| Maltodextrin Drink | Placebo comparator | Dietary Supplement: Maltodextrin Drink30 g carbohydrate equivalent of maltodextrin powder dissolved in ~250 mL of water |
Who may qualify
- Ages
- 60 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- English-literate and able to give informed consent
- Adults 60 to 80 years old (inclusive)
- (If applicable) Postmenopausal
- BMI of 18·5 to 30 kg/m2 (inclusive)
Key exclusion criteria (17 listed)
- Currently participating in another clinical study that involves altering the regular diet and/or involves consuming a dietary supplement or investigated food product as an intervention
- Weight change >3 kg in the past 3 months
- Exercising vigorously over the past 3 months (i.e., engaging in high-intensity exercises for more than 3 hours a week, where high-intensity exercises leave one out of breath and unable to talk or sing during the workout)
- Current smokers or have quit smoking for less than 5 years
- Drinking >2 alcoholic drinks per day (i.e., one drink is defined as either 150 ml of wine, 340 ml of beer/cider or 45 ml of distilled spirit)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Casein Protein Isolate Drink30 g protein equivalent of casein protein isolate dissolved in ~250 mL of water | Dietary supplement | Casein Protein Drink |
| Whey Protein Isolate Drink30 g protein equivalent of whey protein isolate dissolved in ~250 mL of water | Dietary supplement | Whey Protein Drink |
| Soy Protein Isolate Drink30 g protein equivalent of soy protein isolate dissolved in ~250 mL of water | Dietary supplement | Soy Protein Drink |
| Maltodextrin Drink30 g carbohydrate equivalent of maltodextrin powder dissolved in ~250 mL of water | Dietary supplement | Maltodextrin Drink |
Primary outcome
Changes in metabolites found in plasma (plasma metabolomics)
Time frame: Baseline, 15, 30, 60, 90, 120, 180, 240, 300 minutes
Untargeted metabolomics profiling of plasma will be conducted using ultra performance liquid chromatography-quadrupole time of flight-mass spectrometry (UPLC-QTOF-MS)
Changes in metabolites found in urine (urinary metabolomics)
Time frame: Baseline, 60, 120, 180, 240, 300 minutes
Untargeted metabolomics profiling of urine will be conducted using ultra performance liquid chromatography-quadrupole time of flight-mass spectrometry (UPLC-QTOF-MS)
2 secondary outcomes
Cognitive Function
Time frame: Baseline, 15, 60, 120, 180, 240, 300 minutes
Mood
Time frame: Baseline, 15, 60, 120, 180, 240, 300 minutes
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Feb 2026.
- Background: PubMed 37999866Lanng SK, Oxfeldt M, Johansen FT, Risikesan J, Hansen M, Bertram HC. Acute changes in the metabolome following resistance exercise combined with intake of different protein sources (cricket, pea, whey). Metabolomics. 2023 Nov 24;19(12):98. doi: 10.1007/s11306-023-02064-0.
- Individual participant dataSharing planned: No. Electronic copies of the data with identifiable participant information will be kept on NUS OneDrive with access limited only Dr Kim Jung Eun and her research staff. All data will be de-identified prior to statistical analyses.
Related trials for Aging
RecruitingObservational study
PET Imaging in the Baltimore Longitudinal Study of Aging (BLSA)
Aging
Recruiting
Study Evaluating the Effect of Humiome® Post LB on Stress, Anxiety, and Cognition in Aging Adults
Healthy Aging
RecruitingObservational study
Westlake Aging Cohort (WeAC)
Aging, Cognition Improvement
Not yet recruitingPhase 2
Validation & Intervention Testing for Aging, Longevity and Healthspan
Aging, Functional Decline
Recruiting
Feasibility of A Smartphone Application Intervention in Community Settings: A Pretest-Posttest Pilot Study
Aging, Dementia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jung Eun Kim, Ph.D., R.D. principal investigator
National University of Singapore, Department of Food Science and Technology
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Casein Protein Isolate Drink, Whey Protein Isolate Drink and Soy Protein Isolate Drink in people with Aging and Protein Metabolism, run by National University of Singapore at 1 site in Singapore.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 17 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes in metabolites found in plasma (plasma metabolomics) (time frame: Baseline, 15, 30, 60, 90, 120, 180, 240, 300 minutes). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06956131, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Feb 2026; AzTrials last refreshed its copy on 7 Nov 2026.